New hope for tough cancers? early trial of IL-22BP/LNP begins
NCT ID NCT07100210
First seen Jan 11, 2026 · Last updated May 02, 2026 · Updated 12 times
Summary
This early-stage study tests a new drug called IL-22BP/LNP in people with advanced solid tumors (like certain sarcomas, head and neck cancers, and melanomas) that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Only 6 participants will be enrolled, and the study will also look at whether the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.